The 2021 ESMO Congress priority report focuses on updates in genitourinary cancers presented at the virtual conference, held September 16 to 21, 2021.
Atezolizumab/Cabozantinib Displays Promise in High-Risk mCRPC
The combination of atezolizumab and cabozantinib elicited encouraging responses, marked by an unprecedented disease control rate, in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, but most strikingly in patients with high-risk features.
Frontline Immunotherapy Improves Survival in Advanced RCC, But Benefit to Be Determined for Favorable-Risk Subset
Frontline immunotherapy resulted in improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma; however, determining the benefit in those with favorable-risk disease must be examined further.
Pembrolizumab/Axitinib Combo Demonstrates Long-Term OS Benefit in Clear Cell RCC
Patients with clear cell renal cell carcinoma who received the combination of pembrolizumab and axitinib over sunitinib showed a benefit in adjusted overall survival and type and timing of subsequent therapy in a second interim analysis of the phase 3 KEYNOTE-426 study.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.